The relationship between regional bone turnover measured using 18F-fluoride positron emission tomography and changes in BMD is equivalent to that seen for biochemical markers of bone turnover

被引:19
作者
Frost, Michelle L.
Cook, Gary J. R.
Blake, Glen M.
Marsden, Paul K.
Fogelman, Ignac
机构
[1] Guys Hosp, Kings Coll London Sch Med, Osteoporosis Screening & Res Unit, London SE1 9RT, England
[2] Royal Marsden Hosp, Dept Nucl Med, Surrey, England
[3] St Thomas Hosp, Kings Coll London Sch Med, Clin PET Ctr, London, England
关键词
biochemical markers; bone mineral density; bone turnover; osteoporosis;
D O I
10.1016/j.jocd.2006.10.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bone turnover is an important determinant of fracture risk. F-18-fluoride positron emission tomography (F-18-PET) allows the direct assessment of bone turnover at the clinically important skeletal sites such as the lumbar spine. The aim of this study was to determine if the relationship between regional bone turnover measured using F-18-PET and changes in bone mineral density (BMD) is equivalent to that seen for global skeletal measurements of biochemical markers of bone turnover. Forty-three women who had previously had an F-18-PET scan at the lumbar spine, assessment of biochemical markers of bone turnover, and a dual-energy X-ray absorptiometry scan of BMD at the lumbar spine and hip (baseline assessments) were split into 1 of 2 groups: (1) 22 women who commenced treatment for osteoporosis within 2 mo of having the baseline assessments (Treatment group); (2) 21 women who had not taken any treatments for osteoporosis since having the baseline assessments (Untreated group). Sixteen of the women in the Treatment group started risedronate therapy as part of a prospective study they were participating in, whereas the decision to treat the remaining 6 women was made by the subject's treating physician. Subjects had between 2 and 5 BMD scans over a median follow-up time of 4.1 yr to estimate the annual percentage change in BMD since baseline. The relationship between the tertiles of F-18-PET skeletal kinetic parameter K-i, reflecting regional bone turnover, and annual changes in lumbar spine and hip BMD were compared to that seen for bone formation (bone-specific alkaline phosphatase, BSALP) and bone resorption (urinary deoxypyridinoline) markers. Treated women in the highest tertile of both regional (F-18-PET) and global (biochemical markers) bone turnover showed the greatest annual percentage increases in lumbar spine BMD. The annual increase in lumbar spine BMD was 1.8%, 2.2%, and 3.2% for women in the lowest, middle, and highest tertile of BSALP, respectively, which was similar to that obtained for the regional measurement of K-i of 1.7%, 2.2%, and 2.7% respectively. Untreated women in the highest tertile of regional and global bone turnover had larger decreases in lumbar spine BMD compared to those women in the lowest tertile, with a 1.4- to 4.8-fold difference in the annual decrease in BMD between the two. Less consistent patterns were observed when assessing the relationship between regional and global bone turnover with changes in hip BMD. This study has demonstrated that the relationship between regional bone turnover measured directly at the lumbar spine with changes in BMD is similar to that seen for global skeletal bone turnover using biochemical markers.
引用
收藏
页码:46 / 54
页数:9
相关论文
共 44 条
[1]   Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The Fracture Intervention Trial [J].
Bauer, DC ;
Black, DM ;
Garnero, P ;
Hochberg, M ;
Ott, S ;
Orloff, J ;
Thompson, DE ;
Ewing, SK ;
Delmas, PD .
JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (08) :1250-1258
[2]   Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: The fracture intervention trial [J].
Bauer, DC ;
Garnero, P ;
Hochberg, MC ;
Santora, A ;
Delmas, P ;
Ewing, SK ;
Black, DM .
JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 (02) :292-299
[3]   Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis [J].
Bjarnason, NH ;
Sarkar, S ;
Duong, T ;
Mitlak, B ;
Delmas, PD ;
Christiansen, C .
OSTEOPOROSIS INTERNATIONAL, 2001, 12 (11) :922-930
[4]   Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].
Black, DM ;
Cummings, SR ;
Karpf, DB ;
Cauley, JA ;
Thompson, DE ;
Nevitt, MC ;
Bauer, DC ;
Genant, HK ;
Haskell, WL ;
Marcus, R ;
Ott, SM ;
Torner, JC ;
Quandt, SA ;
Reiss, TF ;
Ensrud, KE .
LANCET, 1996, 348 (9041) :1535-1541
[5]  
BLAU M, 1972, Seminars in Nuclear Medicine, V2, P31, DOI 10.1016/S0001-2998(72)80005-9
[6]  
BLAU M, 1962, J NUCL MED, V3, P332
[7]   Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis [J].
Chen, PQ ;
Satterwhite, JH ;
Licata, AA ;
Lewiecki, EM ;
Sipos, AA ;
Misurski, DM ;
Wagman, RB .
JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (06) :962-970
[8]   Hormone replacement therapy in postmenopausal women: Urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density [J].
Chesnut, CH ;
Bell, NH ;
Clark, GS ;
Drinkwater, BL ;
English, SC ;
Johnston, CC ;
Notelovitz, M ;
Rosen, C ;
Cain, DF ;
Flessland, KA ;
Mallinak, NJS .
AMERICAN JOURNAL OF MEDICINE, 1997, 102 (01) :29-37
[9]   HISTOMORPHOMETRIC ASSESSMENT OF TRABECULAR BONE REMODELING IN OSTEOPOROSIS [J].
COMPSTON, JE ;
CROUCHER, PI .
BONE AND MINERAL, 1991, 14 (02) :91-102
[10]   Non-invasive assessment of skeletal kinetics using fluorine-18 fluoride positron emission tomography: evaluation of image and population-derived arterial input functions [J].
Cook, GJR ;
Lodge, MA ;
Marsden, PK ;
Dynes, A ;
Fogelman, I .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (11) :1424-1429